Management of Immunosuppression in Advanced Renal Failure with Volume Overload

Adjustment of Tacrolimus

The American College of Cardiology is not mentioned, however, the guideline recommends reducing the dose of tacrolimus by 30-50% and maintaining mycophenolate at full doses, while closely monitoring trough levels of tacrolimus to achieve ranges of 4-6 ng/mL in patients with advanced renal failure and volume overload 1
Reducing tacrolimus is prioritized because calcineurin inhibitor nephrotoxicity has reversible (vasoconstriction) and irreversible (chronic fibrosis) components, and early reduction can preserve residual renal function 1
Adjusting target trough levels to 4-6 ng/mL (instead of the usual 6-10 ng/mL in the first month or 4-8 ng/mL thereafter) is recommended for patients with advanced renal failure and volume overload 1, 2

Mycophenolate does not have a known negative impact on renal function, according to the guideline 1

Monitoring serum creatinine and tacrolimus levels weekly for 2 weeks, then every 2 weeks for 2 months, is recommended for patients with advanced renal failure and volume overload 1
Monitoring proteinuria monthly for the first 3 months is recommended for patients with advanced renal failure and volume overload 1
Monitoring electrolytes (potassium, magnesium) weekly initially is recommended for patients with advanced renal failure and volume overload 2
Monitoring complete blood counts to detect mycophenolate-induced myelosuppression is recommended for patients with advanced renal failure and volume overload 4

Initiating or intensifying diuretics according to hemodynamic tolerance is recommended for patients with volume overload 4
Considering ACE inhibitors or ARB-II to reduce proteinuria (if present) while closely monitoring creatinine and potassium after initiation is recommended for patients with advanced renal failure and volume overload 1
Volume overload may require dialysis if refractory to diuretics, especially if renal function is severely compromised 5

Completely withdrawing calcineurin inhibitors carries a risk of acute rejection of 3-30% and should be avoided, according to the guideline 1
The KDIGO guidelines recommend continuing calcineurin inhibitors instead of withdrawing them (recommendation 2B) for patients with advanced renal failure and volume overload 5
If rejection occurs, considering adding or restoring corticosteroids is recommended for patients with advanced renal failure and volume overload 5

Completely suspending tacrolimus should be avoided, as excessive reduction significantly increases the risk of rejection, according to the guideline 1
Monitoring drug interactions is crucial, as tacrolimus is metabolized by CYP3A4, and medications such as azole antifungals, macrolides, and non-dihydropyridine calcium channel blockers increase its levels 2, 4
Avoiding allopurinol with azathioprine (if used instead of mycophenolate) is recommended, as it can cause fatal bone marrow suppression 4
Considering renal biopsy if renal function continues to deteriorate despite adjustments to rule out rejection or chronic allograft nephropathy is recommended for patients with advanced renal failure and volume overload 1, 5

Considering conversion from tacrolimus to mTOR inhibitor (sirolimus/everolimus) only if estimated GFR is >40 mL/min/1.73m² and proteinuria <500 mg/g creatinine is recommended for patients with advanced renal failure and volume overload 1
Converting to mTOR inhibitor when proteinuria is already significant (>500 mg/g) may worsen it, according to the guideline 1